Literature DB >> 8353958

A method to quantify deviations from assay linearity.

J S Krouwer1, B Schlain.   

Abstract

We present a statistical method to quantify deviations from linearity for assays that veer from linear assay responses. Our procedure handles the common case of unequally spaced analyte levels and nonconstant variance and provides a least-squares estimate with a confidence interval for the amount of deviation from assay linearity at a specified analyte concentration. This estimate of assay bias due to nonlinearity goes beyond the NCCLS EP6 lack-of-fit test, which tests for only the presence of nonlinearity. Knowing that nonlinearity is present is insufficient; users need to know the magnitude of the bias caused by nonlinearity. Our method can also be used with multifactor designs that estimate other systematic assay effects such as drift and carryover, thus obviating the need for a separate protocol to assess linearity. The procedure is carried out by adding extra columns to the design matrix corresponding to the concentration level(s) of interest. The extra columns, which replace the quadratic column, are orthogonal to all other columns. We describe a general method of constructing the new columns, and illustrate the procedure with a manual ammonia assay example dataset from EP6.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353958

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.

Authors:  Kim M Clark-Langone; Chithra Sangli; Jayadevi Krishnakumar; Drew Watson
Journal:  BMC Cancer       Date:  2010-12-23       Impact factor: 4.430

2.  Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.

Authors:  Travers Ching; Megan E Duncan; Tera Newman-Eerkes; Mollie M E McWhorter; Jeffrey M Tracy; Michelle S Steen; Ryan P Brown; Srivatsa Venkatasubbarao; Nicholas K Akers; Marissa Vignali; Martin E Moorhead; Drew Watson; Ryan O Emerson; Tobias P Mann; B Melina Cimler; Pamela L Swatkowski; Ilan R Kirsch; Charles Sang; Harlan S Robins; Bryan Howie; Anna Sherwood
Journal:  BMC Cancer       Date:  2020-06-30       Impact factor: 4.430

3.  Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.

Authors:  Dejan Knezevic; Audrey D Goddard; Nisha Natraj; Diana B Cherbavaz; Kim M Clark-Langone; Jay Snable; Drew Watson; Sara M Falzarano; Cristina Magi-Galluzzi; Eric A Klein; Christopher Quale
Journal:  BMC Genomics       Date:  2013-10-08       Impact factor: 3.969

4.  A method for measuring the experimental resolution of laboratory assays (clinical biochemical, blood count, immunological, and qPCR) to evaluate analytical performance.

Authors:  Chenxi Sun; Dongxia Wang; Henggui Xu; Guang Yang; Xiaomei Yan; Hui Liu
Journal:  J Clin Lab Anal       Date:  2021-11-01       Impact factor: 2.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.